Optimi Health Corp. (CSE: OPTI | NASDAQ: OPTH) has appointed Melanie Pump to its Board of Directors, the company announced on September 29, 2026. Pump brings more than 25 years of leadership experience spanning technology, digital infrastructure, software, fintech, and emerging growth companies. The appointment signals a continued focus on financial governance as Optimi advances its position in the regulated psychedelic pharmaceutical market. The company also disclosed a change in its Corporate Secretary role.

Key Points

  • Optimi Health Corp. (CSE: OPTI | NASDAQ: OPTH) announced a new board appointment on September 29, 2026
  • Melanie Pump joins the Board of Directors, bringing more than 25 years of finance and governance experience
  • Pump currently serves as CFO of Qu Data Centres and as a director of Mobio Technologies Inc. (TSXV: MBO)
  • Investors may be watching how the strengthened board composition supports Optimi's regulated psychedelic drug commercialisation strategy

Melanie Pump's Finance and Governance Background

Pump currently serves as Chief Financial Officer of Qu Data Centres and holds a board seat at Mobio Technologies Inc. (TSXV: MBO). She previously served as a director of BTCS Inc. (Nasdaq: BTCS). The release states her background combines senior financial leadership with public company governance experience across technology-focused and growth-oriented businesses. CEO Dane Stevens noted that her experience in technology-driven and emerging growth companies, alongside her public company board background, would add valuable perspective as Optimi executes on its strategic priorities in the regulated psychedelic pharmaceutical market.

Optimi's Commercial and Clinical Stage Operations

Optimi describes itself as a Health Canada-licensed pharmaceutical manufacturer producing GMP-grade MDMA and botanical psilocybin drug products at its British Columbia facilities. The company supplies active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Its products are currently prescribed to patients in Australia under that country's Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program. The disclosure suggests Pump's appointment is intended to support Optimi as it continues to scale these regulated commercial activities.

Corporate Secretary Change Alongside Board Addition

Alongside the board appointment, Optimi disclosed that Leah Hodges has resigned as Corporate Secretary. CEO Dane Stevens has been appointed to fill the role on an interim basis. The company stated it thanks Hodges for her service but did not provide further detail regarding the timing or circumstances of the departure. The dual announcement — a board addition and a corporate officer change — reflects governance activity at Optimi as the company advances its operations in the regulated psychedelic sector.